Connect with us

News

Mars travelers can use ‘Star Trek’ Tricorder-like features using smartphone biotech: study

Published

on

Plans to take humans to the Moon and Mars come with numerous challenges, and the health of space travelers is no exception. One of the ways any ill-effects can be prevented or mitigated is by detecting relevant changes in the body and the body’s surroundings, something that biosensor technology is specifically designed to address on Earth. However, the small size and weight requirements for tech used in the limited habitats of astronauts has impeded its development to date.

A recent study of existing smartphone-based biosensors by scientists from Queen’s University Belfast (QUB) in the UK identified several candidates under current use or development that could be also used in a space or Martian environment. When combined, the technology could provide functionality reminiscent of the “Tricorder” devices used for medical assessments in the Star Trek television and movie franchises, providing on-site information about the health of human space travelers and biological risks present in their habitats.

Biosensors focus on studying biomarkers, i.e., the body’s response to environmental conditions. For example, changes in blood composition, elevations of certain molecules in urine, heart rate increases or decreases, and so forth, are all considered biomarkers. Health and fitness apps tracking general health biomarkers have become common in the marketplace with brands like FitBit leading the charge for overall wellness sensing by tracking sleep patterns, heart rate, and activity levels using wearable biosensors. Astronauts and other future space travelers could likely use this kind of tech for basic health monitoring, but there are other challenges that need to be addressed in a compact way.

The projected human health needs during spaceflight have been detailed by NASA on its Human Research Program website, more specifically so in its web-based Human Research Roadmap (HRR) where the agency has its scientific data published for public review. Several hazards of human spaceflight are identified, such as environmental and mental health concerns, and the QUB scientists used that information to organize their study. Their research produced a 20-page document reviewing the specific inner workings of the relevant devices found in their searches, complete with tables summarizing each device’s methods and suitability for use in space missions. Here are some of the highlights.

A chart showing the classification of scientific articles about relevant smartphone-based biosensors used in the Queen’s University Belfast study. | Credit: Biosensors/Queen’s University Belfast

Risks in the Spacecraft Environment

During spaceflight, the environment is a closed system that has a two-fold effect: One, the immune system has been shown to decrease its functionality in long-duration missions, specifically by lowering white blood cell counts, and two, the weightless and non-competitive environment make it easier for microbes to transfer between humans and their growth rates increase. In one space shuttle era study, the number of microbial cells in the vehicle able to reproduce increased by 300% within 12 days of being in orbit. Also, certain herpes viruses, such as those responsible for chickenpox and mononucleosis, have been reactivated under microgravity, although the astronauts typically didn’t show symptoms despite the presence of active viral shedding (the virus had surfaced and was able to spread).

Frequent monitoring of the spacecraft environment and the crew’s biomarkers is the best way to mitigate these challenges, and NASA is addressing these issues to an extent with traditional instruments and equipment to collect data, although often times the data cannot be processed until the experiments are returned to Earth. An attempt has also been made to rapidly quantify microorganisms aboard the International Space Station (ISS) via a handheld device called the Lab-on-a-Chip Application Development-Portable Test System (LOCAD-PTS). However, this device cannot distinguish between microorganism species yet, meaning it can’t tell the difference between pathogens and harmless species. The QUB study found several existing smartphone-based technologies generally developed for use in remote medical care facilities that could achieve better identification results.

Advertisement
NASA astronaut Karen Nyberg uses a fundoscope to image her eye while in orbit to study Visual Impairment Intracranial Pressure (VIIP) Syndrome. Smaller 3D printed retinal imaging adaptors for smartphones are being developed to perform the testing done by large devices similar to the instrument used here. | Credit: NASA

One of the devices described was a spectrometer (used to identify substances based on the light frequency emitted) which used the smartphone’s flashlight and camera to generate data that was at least as accurate as traditional instruments. Another was able to identify concentrations of an artificial growth hormone injected into cows called recominant bovine somatrotropin (rBST) in test samples, and other systems were able to accurately detect cyphilis and HIV as well as the zika, chikungunya, and dengue viruses. All of the devices used smartphone attachments, some of them with 3D-printed parts. Of course, the types of pathogens detected are not likely to be common in a closed space habitat, but the technology driving them could be modified to meet specific detection needs.

The Stress of Spaceflight

A group of people crammed together in a small space for long periods of time will be impacted by the situation despite any amount of careful selection or training due to the isolation and confinement. Declines in mood, cognition, morale, or interpersonal interaction can impact team functioning or transition into a sleep disorder. On Earth, these stress responses may seem common, or perhaps an expected part of being human, but missions in deep space and on Mars will be demanding and need fully alert, well-communicating teams to succeed. NASA already uses devices to monitor these risks while also addressing the stress factor by managing habitat lighting, crew movement and sleep amounts, and recommending astronauts keep journals to vent as needed. However, an all-encompassing tool may be needed for longer-duration space travels.

As recognized by the QUB study, several “mindfulness” and self-help apps already exist in the market and could be utilized to address the stress factor in future astronauts when combined with general health monitors. For example, the popular FitBit app and similar products collect data on sleep patterns, activity levels, and heart rates which could potentially be linked to other mental health apps that could recommend self-help programs using algorithms. The more recent “BeWell” app monitors physical activity, sleep patterns, and social interactions to analyze stress levels and recommend self-help treatments. Other apps use voice patterns and general phone communication data to assess stress levels such as “StressSense” and “MoodSense”.

A Tricorder-like setup is imagined by scientists at Queens University Belfast, utilizing the functionalities of existing smartphone-based biosensors. | Credit: Biosensors/Queens University Belfast

Advances in smartphone technology such as high resolution cameras, microphones, fast processing speed, wireless connectivity, and the ability to attach external devices provide tools that can be used for an expanding number of “portable lab” type functionalities. Unfortunately, though, despite the possibilities that these biosensors could mean for human spaceflight needs, there are notable limitations that would need to be overcome in some of the devices. In particular, any device utilizing antibodies or enzymes in its testing would risk the stability of its instruments thanks to radiation from galactic cosmic rays and solar particle events. Biosensor electronics might also be damaged by these things as well. Development of new types of shielding may be necessary to ensure their functionality outside of Earth and Earth orbit or, alternatively, synthetic biology could also be a source of testing elements genetically engineered to withstand the space and Martian environments.

The interest in smartphone-based solutions for space travelers has been garnering more attention over the years as tech-centric societies have moved in the “app” direction overall. NASA itself has hosted a “Space Apps Challenge” for the last 8 years, drawing thousands of participants to submit programs that interpret and visualize data for greater understanding of designated space and science topics. Some of the challenges could be directly relevant to the biosensor field. For example, in the 2018 event, contestants are asked to develop a sensor to be used by humans on Mars to observe and measure variables in their environments; in 2017, contestants created visualizations of potential radiation exposure during polar or near-polar flight.

While the QUB study implied that the combination of existing biosensor technology could be equivalent to a Tricorder, the direct development of such a device has been the subject of its own specific challenge. In 2012, the Qualcomm Tricorder XPRIZE competition was launched, asking competitors to develop a user-friendly device that could accurately diagnose 13 health conditions and capture 5 real-time health vital signs. The winner of the prize awarded in 2017 was Pennsylvania-based family team called Final Frontier Medical Devices, now Basil Leaf Technologies, for their DxtER device. According to their website, the sensors inside DxtER can be used independently, one of which is in a Phase 1 Clinical Trial. The second place winner of the competition used a smartphone app to connect its health testing modules and generate a diagnosis from the data acquired from the user.

The march continues to develop the technology humans will need to safely explore regions beyond Earth orbit. Space is hard, but it was hard before we went there the first time, and it was hard before we put humans on the moon. There may be plenty of challenges to overcome, but as the Queen’s University Belfast study demonstrates, we may already be solving them. It’s just a matter of realizing it and expanding on it.

Advertisement

Accidental computer geek, fascinated by most history and the multiplanetary future on its way. Quite keen on the democratization of space. | It's pronounced day-sha, but I answer to almost any variation thereof.

Advertisement
Comments

Investor's Corner

Tesla stock tumbles after earnings, one of its sharpest single-day declines

Published

on

Credit: Tesla

Tesla stock (NASDAQ: TSLA) endured one of its sharpest single-day declines in years on July 23, tumbling approximately 14.5 percent and closing near $320 after opening the session around $374. The drop erased more than $140 billion in market value amid heavy trading volume and left the shares at multi-week lows.

The sell-off followed the company’s second-quarter 2026 results, released the previous evening. Tesla reported record revenue of $28.2 billion, up 26 percent year over year, driven by a Q2-record 480,126 vehicle deliveries. Energy storage deployments also rose strongly.

Tesla (TSLA) Q2 2026 earnings results: miss on EPS, beat on revenue

Yet profitability disappointed sharply. Operating income fell 57 percent to $398 million, compressing the operating margin to just 1.4 percent. Non-GAAP earnings per share came in at $0.33, well below the roughly $0.53 analysts had expected. Free cash flow turned negative by $1.1 billion as capital expenditures surged 142 percent to $5.8 billion, largely tied to accelerated spending on artificial intelligence, robotics, and autonomous systems.

The losses on capex were expected, as Tesla said it would be spending heavily in 2026.

Advertisement

Investors also reacted to lingering uncertainty surrounding key product timelines. During the Earnings Call, management reiterated ambitions for Robotaxi deployment and the Optimus humanoid robot, but offered limited new concrete milestones, renewing questions about execution pace that have long accompanied Tesla’s ambitious roadmap.

The magnitude of the decline places it among Tesla’s more severe one-day percentage losses since its 2010 initial public offering. Historically, the two largest single-day drops (split-adjusted) remain September 8, 2020, when shares fell 21.1 percent amid broader market volatility and valuation concerns, and January 13, 2012, with a 19.3 percent plunge during the company’s early growth struggles.

Other notable declines include an 18.6 percent drop on March 16, 2020, at the onset of pandemic-related market turmoil. Thursday’s move ranks roughly ninth on the all-time list but stands out as the steepest in more than a year.

Despite the short-term pain, Tesla’s long-term trajectory has repeatedly recovered from such volatility. The latest results underscore both the strength of its core automotive and energy businesses and the near-term costs of heavy investment in next-generation technologies.

Advertisement
Continue Reading

Elon Musk

Elon Musk is not happy about this Tesla Full Self-Driving approval delay

Published

on

Credit: Tesla

Elon Musk clapped back at France’s decision to withhold the approval for Tesla’s Full Self-Driving (FSD) Supervised system, projecting a clear and blunt message to French Transport Minister Phillippe Tabarot, after he publicly rejected the technology in its current form.

Tabarot outlines several concerns with Tesla Full Self-Driving in a detailed video statement, where he said, “The safety trade-offs are not yet sufficient to authorize it as it currently stands,” he said. He emphasized that FSD is not a true self-driving system and that the driver remains fully responsible.

Key issues Tabarot also brought up included allowing speeding when surrounding traffic exceeds limits and what he believes are insufficient guarantees of driver attention during complex urban maneuvers such as lane changes, intersections, and roundabouts.

Advertisement

While acknowledging technological progress and France’s support for autonomous innovation, Tabarot stressed that deployment must prioritize road safety. He noted ongoing technical discussions with Tesla, the Netherlands, and other European partners, with further ecosystem meetings planned for the fall.

Musk’s rebuke highlights the human cost of regulatory caution. Tesla’s latest safety reports provide compelling data supporting accelerated adoption. In the most recent 12-month period, vehicles using FSD (Supervised) recorded one major collision per approximately 5.1 million miles driven, dramatically better than the U.S. national average of one crash per 698,000 miles.

Even Tesla vehicles driven manually with active safety features outperform the average by a wide margin. These figures come from billions of real-world miles of telemetry, showing FSD vehicles involved in far fewer incidents than both manual Teslas and the broader U.S. fleet.

Critics argue Tesla’s comparisons require careful scrutiny regarding reporting thresholds and fleet demographics, yet the data consistently positions FSD as a potential lifesaver. With road fatalities remaining a leading cause of death worldwide, Musk contends that proven safer technology should not face prolonged bureaucratic hurdles.

France’s measured approach reflects the broader European regulatory caution, which many, especially Musk, have been critical of in the past. However, as autonomous systems from Tesla and competitors like Waymo demonstrate superior safety in independent studies, pressure is mounting for harmonized approvals.

Advertisement

Musk’s warning carries the belief that every month of delay may equate to avoidable tragedies on European roads.

Continue Reading

Investor's Corner

Google’s massive stake in SpaceX will shock you

Published

on

Credit: SpaceX

In a striking revelation that underscores the lucrative crossover between Big Tech and space exploration, Alphabet Inc., Google’s parent company, disclosed a massive $94.1 billion equity stake in SpaceX following the rocket company’s blockbuster initial public offering earlier this year.

The disclosure came in Alphabet’s quarterly filing, marking the first time the long-held private investment has been publicly valued at market prices. Google was an early backer, investing alongside Fidelity in 2015 with roughly $500-900 million at a time when SpaceX was valued around $12 billion.

That bet has delivered extraordinary returns, roughly a hundredfold, transforming a strategic play on satellite internet and launch capabilities into one of Alphabet’s largest assets.

Advertisement

Of the total holding, approximately $80 billion remains subject to short-term post-IPO lockup restrictions, preventing near-term sales. An additional $14.1 billion faces longer-term restrictions, extending into the third quarter of 2027. This structure limits immediate liquidity but protects against market volatility as SpaceX transitions into public trading.

The SpaceX position contributed significantly to gains in Alphabet’s broader investment portfolio, which also includes a major stake in AI leader Anthropic. Combined, these holdings helped drive nearly $100 billion in investment gains during the second quarter, providing a substantial boost to net income amid ongoing AI spending pressures.

Elon Musk sends first warning to SpaceX short sellers

Analysts view the disclosure as validation of Alphabet’s venture strategy beyond its core search and cloud businesses. The investment aligns with deeper ties, including reported multi-billion-dollar deals for AI computing capacity on SpaceX infrastructure. As SpaceX advances Starship flights, Starlink expansion, and ambitious Mars goals under Elon Musk, Google’s stake positions it to benefit from the commercialization of space.

For Alphabet, the windfall highlights how patient, forward-looking bets in transformative sectors can yield outsized rewards. While lockups temper short-term impact, the holding cements SpaceX as a cornerstone of Alphabet’s diversified portfolio in an era where aerospace, AI, and connectivity increasingly intersect. Investors will watch closely as restrictions lift and SpaceX’s public performance unfolds.

Advertisement
Continue Reading